Stockscreener 앱 받기
9.85
2.67%
-0.27
전일 마감가:
$10.12
열려 있는:
$10.16
하루 거래량:
108.90K
Relative Volume:
0.61
시가총액:
$241.38M
수익:
$31,000
순이익/손실:
$-246.41M
주가수익비율:
-0.7733
EPS:
-12.7377
순현금흐름:
$-134.42M
1주 성능:
-10.54%
1개월 성능:
-36.41%
6개월 성능:
-51.09%
1년 성능:
-22.56%
1일 변동 폭
$9.81
$10.16
1주일 범위
$9.81
$11.22
52주 변동 폭
$9.81
$45.00
Lyell Immunopharma Inc Stock (LYEL) Company Profile
명칭
Lyell Immunopharma Inc
전화
650 695-0677
주소
201 HASKINS WAY, SOUTH SAN FRANCISCO
Compare LYEL vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LYEL
Lyell Immunopharma Inc
|
9.85 | 241.38M | 31,000 | -246.41M | -134.42M | -12.74 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Lyell Immunopharma Inc Stock (LYEL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-10 | 개시 | Needham | Buy |
| 2026-03-09 | 개시 | Citizens | Mkt Outperform |
| 2025-12-09 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2024-10-30 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2024-06-27 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-08-28 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2022-11-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-11-11 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-10-17 | 개시 | H.C. Wainwright | Buy |
| 2021-07-12 | 개시 | BofA Securities | Buy |
| 2021-07-12 | 개시 | Goldman | Buy |
| 2021-07-12 | 개시 | JP Morgan | Overweight |
| 2021-07-12 | 개시 | Morgan Stanley | Overweight |
모두보기
Lyell Immunopharma Inc 주식(LYEL)의 최신 뉴스
Wall Street Analysts Think Lyell Immunopharma (LYEL) Could Surge 176.02%: Read This Before Placing a Bet - Eastern Progress
A cancer-therapy talk will stream live Sept. 15 from Lyell Immunopharma. - Stock Titan
Lyell Immunopharma To Participate in the Baird 2026 Global Healthcare Conference - Yahoo Finance
H.C. Wainwright reiterates Lyell Immunopharma stock rating at buy By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Lyell Immunopharma stock rating at buy - Investing.com
Lyell completes LYL273 manufacturing transfer, eyes 2027 FDA meeting By Investing.com - Investing.com Nigeria
symbol__ Stock Quote Price and Forecast - CNN
Lyell Immunopharma CMO David Shook sells $6,350 in shares By Investing.com - Investing.com South Africa
Lyell Immunopharma CMO David Shook sells $6,350 in shares - Investing.com
Lyell Immunopharma (LYEL) CMO sells shares to cover taxes - Stock Titan
Lyell Immunopharma (LYEL) awards CMO new 47,500-share option - Stock Titan
Lyell Immunopharma (LYEL) CMO discloses stock, RSUs and option awards - Stock Titan
Lyell completes LYL273 manufacturing transfer, eyes 2027 FDA meeting - investing.com
Lyell Immunopharma advances LYL273 CAR T program - TipRanks
Lyell Immunopharma Completes Manufacturing Transfer for - GlobeNewswire
Lyell Immunopharma, Inc. (LYEL) Stock Price & News - Syfe
Lyell Immunopharma stock holds steady as investors await fresh clinical and cash-flow signals - AD HOC NEWS
This Insider Has Just Sold Shares In Lyell Immunopharma - simplywall.st
Lyell Immunopharma (LYEL) CEO sells shares for taxes, keeps 63,899 - Stock Titan
Lyell (LYEL) Outlook: Closes 4.57% Lower at $14.82 in the Latest Session; Next Session: the $14.08 to $15.56 Range Remains in Focus at the ClosePassive Flow - vinanet.vn
Lyell (LYEL) Technicals: Ends Up by 1.17% at $15.53 on the Day; Boundary Watch: the Price Remains Bounded by the Supplied Support and Resistance in the Current UpdateVol Target Rebalance - siam.in
Lyell Immunopharma (LYEL): Foresite funds and Tananbaum report 2.7% ownership - Stock Titan
Citizens reiterates Lyell Immunopharma stock rating on pipeline progress By Investing.com - Investing.com Canada
Lyell Immunopharma, Inc. (NASDAQ:LYEL) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Lyell Immunopharma (LYEL) Slides 4.77% to $14.17 as Biotech Risk Appetite FadesTriple Top - dars.gov.et
Lyell Immunopharma VP Bulis sells $8,905 of common stock By Investing.com - Investing.com UK
Lyell Immunopharma VP Veronica Sanchez Bulis Sells 621 Shares for Tax Withholding on August 10, 2026 - Kalkine Media
Lyell Immunopharma COO Stephen J. Hill Sells Shares to Cover Tax Withholding on RSU Settlement - Kalkine Media
Lyell Immunopharma (LYEL) CSO auto-sells shares to cover RSU tax withholding - Stock Titan
Lyell Immunopharma VP Bulis sells $8,905 of common stock - Investing.com
Lyell Immunopharma CSO Executes Automatic Stock Sale to Meet Tax Withholding Requirements - Kalkine Media
Lyell Immunopharma (LYEL) VP auto-sells 621 shares to cover RSU taxes - Stock Titan
Lyell Immunopharma (LYEL) COO auto-sells 89 shares for RSU tax withholding - Stock Titan
Lyell Immunopharma (LYEL) CEO sells shares to cover RSU tax withholding - Stock Titan
Renaissance Technologies LLC Buys 76,921 Shares of Lyell Immunopharma, Inc. $LYEL - MarketBeat
LYEL Q2 2026 Earnings: Narrower-Than-Expected Loss Drives 3.31% Share GainEarnings Quality Score - careplusvn.com
Lyell Immunopharma, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Lyell Immunopharma earnings beat by $0.22, revenue fell short of estimates - Investing.com Canada
Possible Signal As Lyell Immunopharma Insiders Sell US$527k In Stock - webull.com
Lyell Immunopharma (NASDAQ:LYEL) Posts Earnings Results, Beats Expectations By $0.10 EPS - MarketBeat
Lyell Immunopharma, Inc. expected to post a loss of $2.08 a shareEarnings Preview - TradingView
Lyell Immunopharma: Q2 Earnings Snapshot - AOL.com
Lyell Immunopharma reports Q2 2026 net loss $44.8M, cash $228.0M; clinical milestones advance - TradingView
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026 - manilatimes.net
BRIEF-Lyell Immunopharma Q2 Operating Expenses USD 47.341 Million - TradingView
This Lyell Immunopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday - Benzinga
Lyell Immunopharma (NASDAQ:LYEL) Earns Buy Rating from Analysts at Stifel Nicolaus - MarketBeat
Stifel Initiates Lyell Immunopharma(LYEL.US) With Buy Rating, Announces Target Price $36 - Moomoo
Stifel Initiates Lyell Immunopharma at Buy With $36 Price Target - Yahoo Finance
LYELL IMMUNOPHARMA, INC. : STIFEL INITIATES COVERAGE WITH BUY RATING; TARGET PRICE $36 - Bitget
Stifel initiates Lyell Immunopharma stock with buy rating on CAR T therapy - Investing.com South Africa
Lyell Immunopharma Inc (LYEL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.06%
2.55%
자본화:
|
볼륨(24시간):